Behrad Derakhshan - 07 Feb 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Business Officer
Signature
/s/ John R Moore Attorney-in-Fact for Behrad Derakhshan
Issuer symbol
EWTX
Transactions as of
07 Feb 2024
Net transactions value
-$180,958
Form type
4
Filing time
09 Feb 2024, 17:42:31 UTC
Previous filing
18 Aug 2023
Next filing
03 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $1,158 +600 +8.5% $1.93 7,620 07 Feb 2024 Direct F1, F2
transaction EWTX Common Stock Sale $12,000 -600 -7.9% $20.00 7,020 07 Feb 2024 Direct
transaction EWTX Common Stock Options Exercise $8,878 +4,600 +66% $1.93 11,620 08 Feb 2024 Direct
transaction EWTX Common Stock Sale $92,049 -4,600 -40% $20.01 7,020 08 Feb 2024 Direct F3
transaction EWTX Common Stock Options Exercise $9,264 +4,800 +68% $1.93 11,820 09 Feb 2024 Direct
transaction EWTX Common Stock Sale $96,209 -4,800 -41% $20.04 7,020 09 Feb 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -600 -0.39% $0.000000 154,417 07 Feb 2024 Common Stock 600 $1.93 Direct F5
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -4,600 -3% $0.000000 149,817 08 Feb 2024 Common Stock 4,600 $1.93 Direct F5
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -4,800 -3.2% $0.000000 145,017 09 Feb 2024 Common Stock 4,800 $1.93 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 30, 2023.
F2 Includes 850 shares purchased on November 15, 2022, 1,304 shares purchased on May 15, 2023 and 1,608 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.135, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.